Either way, fans are excited to see what the cunning con-man has been up to as of late! Being that filming for Season 4 has ...

Catalyst Pharmaceuticals ( NASDAQ: CPRX) said that the company and licensor SERB S.A. signed a settlement agreement with ...

As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035CORAL GABLES, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst ...

Catalyst Pharmaceuticals agreed to settle its litigation against Lupin Pharmaceuticals over Lupin's application to market a generic version of Catalyst's Lambert-Eaton myasthenic syndrome drug.

A seductive thief takes center stage in this bold anime noir masterpiece that is the perfect next-watch for fans of Cowboy ...

As the patent for semaglutide nears its end, Novo Nordisk's dominance in the weight-loss market is being challenged. The ...

Lupin has partnered with Swiss major Sandoz Group AG to market and commercialise Lupin’s biosimilar ranibizumab across ...

Sandoz will oversee commercialization of the product across the European Union (excluding Germany), Switzerland, Norway, ...

As fans eagerly await the continuation of Assane Diop's captivating journey, the filming for the fourth and final season of Netflix's 'Lupin' is underway and expected to conclude ...

Glucagon is indicated for the treatment of severe hypoglycemia in patients with diabetes mellitus and as a diagnostic aid for ...

Ranibizumab's indications encompass the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration, and ...

Lupin collaborates with Sandoz to commercialize biosimilar ranibizumab in multiple regions. Sandoz to handle ...